Drugs / ONO-7018
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06622226 | Nov 2024 → Jul 2027 expected | non-Hodgkin lymphoma | Ono Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05515406 | Feb 2023 → Aug 2025 | B-cell chronic lymphocytic leukemia | Ono Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ONO-7018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05515406 ↗ |
| Action | Inhibit | “selective inhibitor of mucosa associated lymphoid tissue protein 1 (MALT1)” NCT05515406 ↗ |
| Route | Oral | “ONO-7018 tablet(s) are administered orally” NCT05515406 ↗ |
| Target | MALT1 | “selective inhibitor of mucosa associated lymphoid tissue protein 1 (MALT1)” NCT05515406 ↗ |